PTEN is inversely correlated with the cell survival factor Akt/PKB and is inactivated via multiple mechanisms in haematological malignancies

Human Molecular Genetics

Volumn 8, Issue 2, 1999, Pages 185-193

  Dahia, Patricia L M ^a,d   Aguiar, Ricardo C T ^a   Alberta, John ^a   Kum, Jennifer B ^a,d   Caron, Stacey ^a   Sill, Heinz ^b   Marsh, Debbie J ^a,d   Ritz, Jerome ^a   Freedman, Arnold ^a   Stiles, Charles ^a   Eng, Charis ^a,c,d  

^a HARVARD MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF GRAZ   (Austria)

^c UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^d OHIO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MESSENGER RNA; PHOSPHOPROTEIN; PROTEIN SERINE THREONINE KINASE;

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; CELL SURVIVAL; CONTROLLED STUDY; GENE DELETION; GENE MUTATION; GENE REPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; HUMAN TISSUE; LEUKEMIA CELL LINE; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; TUMOR SUPPRESSOR GENE;

STAPHYLOCOCCUS PHAGE 3A;

EID: 0032898096     PISSN: 09646906     EISSN: None     Source Type: Journal    
DOI: 10.1093/hmg/8.2.185     Document Type: Article

References (53)

1. Rabbitts, T.H. (1994) Chromosomal translocations in human cancer. Nature, 372, 143-149.
2. Aguiar, R.C., Dahia, P.L., Bendit, I., Beitler, B., Dorlhiac, P., Bydlowski, S. and Chamone, D. (1995) Further evidence for the lack of correlation between the breakpoint site within M-BCR and CML prognosis and for the occasional involvement of p53 in transformation. Cancer Genet. Cytogenet., 84, 105-112.
3. Drexler, H.G. (1998) Review of alterations of cyclin-dependent kinase inhibitor 1NK4 family genes p15, p16, p18 and p19 in human leukemia-lymphoma cells. Leukemia, 12, 845-849.
4. Speaks, S.L., Sanger, W.G., Masih, A.S., Harrington, D.S., Hess, M. and Armitage, J.O. (1992) Recurrent abnormalities of chromosome bands 10q 23-25 in non-Hodgkin's lymphoma. Genes Chromosomes Cancer, 5, 239-243.
5. Aguiar, R.C., Chase, A., Oscier, D.G., Carapeti, M., Goldman, J.M. and Cross, N.C. (1997) Characterization of a t(10;12)(q24;p13) in a case of CML in transformation. Genes Chromosomes Cancer, 20, 408-411.
6. Steck, P.A., Pershouse, M.A., Jasser, S.A., Yung, W.K.A., Lin, H., Ligon, A.H., Langford, L.A., Baumgard, M.L., Hattier, T., Davis, T., Frye, C., Hu, R., Swedlund, B., Teng, D.H.F. and Tavtigian, S.V. (1997) Identification of a candidate tumour suppressor gene. MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nature Genet., 15, 356-362.
7. Li, J., Yen, C., Liaw, D., Podsypanina, K., Bose, S., Wang, S., Puc, J., Miliaresis, C., Rodgers, L., McCombie, R., Bigner, S.H., Giovanella, B.C., Ittman, M., Tycko, B., Hibshoosh, H., Wigler, M.H. and Parsons, R. (1997) PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast and prostate cancer. Science, 275, 1943-1947.
8. Li, D.-M. and Sun, H. (1997) TEP1, encoded by a candidate tumor suppressor locus, is a novel protein tyrosine phosphatase regulated by transforming growth factor B. Cancer Res., 57, 2124-2129.
9. Myers, M.P., Stolarov, J., Eng, C., Li, J., Wang, S.I., Wigler, M.H., Parsons, R. and Tonks, N.K. (1997) PTEN, the tumor suppressor from human chromosome 10q23, is a dual specificity phosphatase. Proc. Natl Acad. Sci. USA. 94, 9052-9057.
10. Rasheed, B.K., Stenzel, T.T., McLendon, R.E., Parsons, R., Friedman, A.H., Friedman, H.S., Bigner, D.D. and Bigner, S.H. (1997) PTEN gene mutations are seen in high-grade but not in low-grade gliomas. Cancer Res., 57, 4187-4190.
11. Risinger, J.I., Hayes, A.K., Berchuk, A. and Barrett, J.C. (1997) PTEN/MMAC1 mutations in endometrial cancers. Cancer Res., 57, 4736-4738.
12. Liaw, D., Marsh, D.J., Li, J., Dahia, P.L.M., Wang, S.I., Zheng, Z., Bose, S., Call, K.M., Tsou, H.C., Peacocke, M., Eng, C. and Parsons, R. (1997) Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome. Nature Genet., 16, 64-67.
13. Marsh, D.J., Dahia, P.L., Zheng, Z., Liaw, D., Parsons, R., Gorlin, R.J. and Eng, C. (1997) Germline mutations in PTEN are present in Bannayan-Zonana syndrome. Nature Genet., 16, 333-334.
14. Wang, S.I., Puc, J., Li, J., Bruce, J.N., Cairns, P., Sidransky, D. and Parsons, R. (1997) Somatic mutations of PTEN in glioblastoma multiforme. Cancer Res., 57, 4183-1186.
15. Myers, M.P. and Tonks, N.K. (1997) PTEN: sometimes taking it off can be better than putting it on. Am. J. Hum. Genet., 61, 1234-1238.
16. Furnari, F.B., Lin, H., Huang, H.S. and Cavenee, W.K. (1997) Growth suppression of glioma cells by PTEN requires a functional phosphatase catalytic domain. Proc. Natl Acad. Sci. USA, 94, 12479-12484.
17. Fauman, E.B. and Saper, M.A. (1996) Structure and function of the protein tyrosine phosphatases. Trends Biochem. Sci., 21, 413-417.
18. Burgering, B.M. and Coffer, P.J. (1995) Protein kinase B (c-Akt) in phosphatidyl-3-OH kinase signal transduction. Nature, 376, 599-602.
19. Kulik, G., Klippel, A. and Weber, M.J. (1997) Antiapoptopic signalling by the insulin-like growth factor 1 receptor, phosphatidylinositol 3-kinase, and Akt. Mol. Cell. Biol., 17, 1595-1606.
20. Alessi, D.R., Andjelkovic, M., Caudwell, B., Cron, P., Morrice, N., Cohen, P. and Hemmings, B.A. (1996) Mechanism of activation of protein kinase B by insulin and IGF-1. EMBO J., 15, 6541-6551.
21. Franke, T.F., Yang, S.I., Chan, T.O., Datta, K., Kazlauskas, A., Morrison, D.K., Kaplan, D.R. and Tsichlis, P.N. (1995) The protein kinase encoded by the Akt proto-oncogene is a target of the PDGF-activated phosphatidylinositol 3-kinase. Cell, 81, 727-736.
22. Stambolic, V., Suzuki, A., de la Pompa, J.L., Brothers, G.M., Mirtsos, C., Sasaki, T., Ruland, J., Penniger, J.M., Siderovski, D.P. and Mak, T.W. (1998) Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN. Cell, 95, 29-39.
23. Dahia, P.L., Marsh, D.H., Zheng, Z., Zedenius, J., Komminoth, P., Frisk, T., Wallin, G., Parsons, R., Longy, M., Larsson, C. and Eng, C. (1997) Somatic deletions and mutations in the Cowden disease gene, PTEN, in sporadic thyroid tumors. Cancer Res., 57, 4710-4713.
24. Marsh, D.J., Zheng, Z., Zedenius, J., Kremer, H., Padberg, G.W., Larsson, C., Longy, M. and Eng, C. (1997) Differential loss of heterozygosity in the region of the Cowden locus within 10q22-23 in follicular thyroid adenomas and carcinomas. Cancer Res., 57, 500-503.
25. Uphoff, C.C., MacLeod, R.A., Denkmann, S.A., Golub, T.R., Borkhardt, A., Janssen, J.W. and Drexler, H.G. (1997) Occurrence of TEL-AML1 fusion resulting from (12:21) translocation in human early B-lineage leukemia cell lines. Leukemia, 11, 441-447.
26. Domer, P.H., Fakharzadeh, S.S., Chen, C.S., Jockel, J., Johansen, L., Silverman, G.A., Kersey, J.H. and Korsmeyer, S.J. (1993) Acute mixed-lineage leukemia t(4;11)(q21;q23) generates an MLL-AF4 fusion product. Proc. Natl Acad. Sci. USA, 90, 7884-7888.
27. Drexler, H.G. (1994) Leukemia cell lines: in vitro models for the study of chronic myeloid leukemia. Leukemia Res., 18, 919-927.
28. Hamlyn, P.H. and Rabbitts, T.H. (1983) Translocation joins c-myc and immunoglobulin gamma 1 genes in a Burkitt lymphoma revealing a third exon in the c-myc oncogene. Nature, 304, 135-139.
29. Sill, H., Goldman, J.M. and Cross, N.C. (1995) Homozygous deletions of the p16 tumor-suppressor gene are associated with lymphoid transformation of chronic myeloid leukemia. Blood, 85, 2013-2016.
30. Gronbaek, K., Zeuthen, J., Guldberg, P., Ralfkiaer, E. and Hou-Jensen, K. (1998) Alterations of the MMAC1 PTEN gene in lymphoid malignancies. Blood, 91, 4388-4390.
31. Di Cristofano, A., Pesce, B., Coron-Cardo, C. and Pandolfi, P.P. (1998) PTEN is essential for embryonic development and tumour suppression. Nature Genet., 19, 348-355.
32. Whang, Y.E., Wu, X., Suzuki, H., Reiter, R.E., Tran, C., Vessella, R.L., Said, J.W., Isaacs, W.B. and Sawyers, C.L. (1998) Inactivation of the tumor suppressor PTEN/MMAC1 in advanced human prostate cancer through loss of expression. Proc. Natl Acad Sci. USA, 95, 5246-5250.
33. Cairns, P., Okami, K., Halachmi, S., Halachmi, N., Esteller, M., Herman, J.G., Jen, J., Isaacs, W.B., Bova, G.S. and Sidransky, D. (1997) Frequent inactivation of PTEN/MMAC1 in primary prostate cancer. Cancer Res., 47, 4997-5000.
34. Maehama, T. and Dixon, J.E. (1998) The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate. J. Biol. Chem., 273, 13375-13378.
35. Alessi, D.R. and Cohen, P. (1998) Mechanism of activation and function of protein kinase B. Curr. Opin. Genet. Dev., 8, 55-62.
36. Bellacosa, A., Testa, J.R., Staal, S.P. and Tsichlis, P.N. (1991) A retroviral oncogene, akt, encoding a serine-threonine kinase containing an SH2-like region. Science, 254, 274-277.
37. Franke, T.F., Kaplan, D.R., Cantley, L.C. and Toker, A. (1997) Direct regulation of the Akt proto-oncogene product by phosphatidylinositol 3,4-bisphosphate. Science, 275, 665-668.
38. Kitamura, T., Ogawa, W., Sakaue, H., Hino, Y., Kuroda, S., Takata, M., Matsumoto, M., Maeda, T., Konishi, H., Kikkawa, U. and Kasuga, M. (1998) Requirement for activation of the serine-threonine kinase Akt (protein kinase B) in insulin stimulation of protein synthesis but not of glucose transport. Mol. Cell. Biol., 18, 3708-3717.
39. Dudek, H., Datta, S.R., Franke, T.F., Birnbaum, M.J., Yao, R., Cooper, G.M., Segal, R.A., Kaplan, D.R. and Greenberg, M.E. (1997) Regulation of neuronal survival by the serine-threonine protein kinase Akt. Science, 275, 661-665.
40. Kennedy, S.G., Wagner, A.J., Conzen, S.D., Jordan, J., Bellacosa, A., Tsichlis, P.N. and Hay, N. (1997) The PI 3-kinase/Akt signaling pathway delivers an anti-apoptopic signal. Genes Dev., 11, 701-713.
41. Datta, S.R., Dudek, H., Tao, X., Masters, S., Fu, H., Gotoh, Y. and Greenberg, M.E. (1997) Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell, 91, 231-241.
42. Konishi, H., Matsuzaki, H., Tanaka, M., Takemura, Y., Kuroda, S., Ono, Y. and Kikkawa, U. (1997) Activation of protein kinase B (Akt/RAC-protein kinase) by cellular stress and its association with heat shock protein Hsp27. FEBS Lett., 410, 493-498.
43. Bellacosa, A., de Feo, D., Godwin, A.K., Bell, D.W., Cheng, J.Q., Altomare, D.A., Wan, M., Dubeau, L., Scambia, G., Masciullo, V., Ferrandina, G., Benedetti-Panici, P., Mancuso, S., Neri, G. and Testa, J.R. (1995) Molecular, alterations of the AKT2 oncogene in ovarian and breast carcinomas. Int. J. Cancer. 64, 280-285.
44. Cheng, J.Q., Ruggeri, B., Klein, W.M., Sonoda, G., Altomare, D.A., Watson, D.K. and Testa, J.R. (1996) Amplification of AKT2 in human pancreatic cells and inhibition of AKT2 expression and tumorigenicity by antisense RNA. Proc. Natl Acad. Sci. USA, 93, 3636-3641.
45. Neel, B.G. (1997) Role of phosphatases in lymphocyte activation. Curr. Opin. Immunol., 9, 405-420.
46. Pani, G., Siminovitch, K.A. and Paige, C.J. (1997) The motheaten mutation rescues B cell signaling and development in CD45-deficient mice. J. Exp. Med., 186, 581-588.
47. Tamura, M., Gu, J., Matsumoto, K., Aota, S., Parsons, R. and Yamada, K.M. (1998) Inhibition of cell migration, spreading, and focal adhesion by tumor suppressor PTEN. Science, 280, 1614-1617.
48. Wormann, B., Anderson, J.M., Liberty, J.A., Gajl-Peczalska, K., Brunning, R.D., Silberman, T.L., Arthur, D.C. and LeBien, T.W. (1989) Establishment of a leukemic cell model for studying pre-B to B cell differentiation. J. Immunol., 142, 110-117.
49. Marsh, D.J., Roth, S., Lunetta, K.L., Hemminki, A., Dahia, P.L., Sistonen, P., Zheng, Z., Caron, S., van Orsouw, N.J., Bodmer, W.F., Cottrell, S.E., Dunlop, M.G., Eccles, D., Hodgson, S.V., Jarvinen, H., Kellokumpu, I., Markie, D., Neale, K., Phillips, R., Rozen, P., Sygnal, S., Vijg, J., Tomlinson, I.P., Aaltonen, L.A. and Eng, C. (1997) Exclusion of PTEN and 10q22-24 as the susceptibility locus for juvenile polyposis syndrome. Cancer Res., 57, 5017-5021.
50. Dahia, P.L., FitzGerald, M.G., Zhang, X., Marsh, D.J., Zheng, Z., Pietsh, T., von Deimling, A., Haluska, F.G., Haber, D.A. and Eng, C. (1948) A highly conserved processed PTEN pseudogene is located on chromosome hand 9p21. Oncogene, 16, 2403-2406.
51. Aguiar, R.C., Dahia, P.L., Sill, H., Toledo, S.P., Goldman, J.M. and Cross, N.C. (1996) Deletion analysis of the p16 tumour suppressor gene in phaeochromocytomas. Clin. Endocrinol., 45, 93-96.
52. Otterson, G.A., Khleif, S.N., Chen, W., Coxon, A.B. and Kaye, F.J. (1995) CDKN2 gene silencing in lung cancer by DNA hypermethylation and kinetics of p16INK4 protein induction by 5-aza 2'deoxycytidine. Oncogene, 11, 1211-1216.
53. Woloschak, M., Yu, A., Xiao, J. and Post, K.D. (1996) Frequent loss of the p16INK4a gene product in human pituitary tumors. Cancer Res., 56, 2493-2496.